<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05799664</url>
  </required_header>
  <id_info>
    <org_study_id>BC-TLD-02</org_study_id>
    <nct_id>NCT05799664</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Effectiveness of TLD Radiofrequency Ablation in the Treatment of COPD</brief_title>
  <official_title>A Multicenter, Randomized, Single-blind, Sham-controlled Clinical Trial to Evaluate the Safety and Effectiveness of Targeted Lung Denervation Radiofrequency Ablation Devices in the Treatment of Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hangzhou Broncus Medical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hangzhou Broncus Medical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to evaluate the safety and effectiveness of Targeted Lung&#xD;
      Denervation (TLD) for COPD patients using the lung denervation radiofrequency ablation&#xD;
      device.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2023</start_date>
  <completion_date type="Anticipated">August 2026</completion_date>
  <primary_completion_date type="Anticipated">February 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Forced expiratory volume in first second (FEV1) relative to baseline</measure>
    <time_frame>6 Months</time_frame>
    <description>Defined as change in FEV1 at 6 months relative to baseline in the experimental group, compared to the control group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first moderate or severe COPD exacerbation, first severe COPD exacerbation and first respiratory-related hospitalization.</measure>
    <time_frame>12 Months</time_frame>
    <description>Defined as a comparison between study arms of the survival distributions for events based on log-rank tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in St. George's Respiratory Questionnaire COPD Version (SGRQ-C) Total score</measure>
    <time_frame>6 and 12 Months</time_frame>
    <description>Defined as a comparison between study arms of the mean change in SGRQ-C from baseline.&#xD;
The SGRQ-C is a questionnaire developed to measure health status (quality of life) in COPD patients with a total and three component scores for: symptoms, activity and impacts; each score ranges from 0 (no impairment) to 100 (worst possible).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in modified Medical Research Council (mMRC) scale Total score</measure>
    <time_frame>6 and 12 Months</time_frame>
    <description>Defined as a comparison between study arms of the mean change in mMRC from baseline.&#xD;
The modified Medical Research Council (mMRC) scale is recommended for conducting assessments of dyspnea and disability and functions. Total score ranging 0 to 4. The higher the score, the more deterioration in severity of dyspnea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in COPD Assessment Test (CAT) Total score</measure>
    <time_frame>6 and 12 Months</time_frame>
    <description>Defined as a comparison between study arms of the mean change in CAT from baseline.&#xD;
The CAT is a disease-specific HRQL with eight questions; each score ranges from 0 (no impairment) to 5 (worst possible). The CAT has a scoring range of 0-40. Higher scores denote a more severe impact of COPD on a patient's life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulmonary Function</measure>
    <time_frame>6 and 12 Months</time_frame>
    <description>Defined as a comparison between study arms of the mean change in FEV1%pred, FVC(%pred), RV(%pred) from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6-minute walk distance (6MWD)</measure>
    <time_frame>6 and 12 Months</time_frame>
    <description>Defined as a comparison between study arms of the mean change in 6MWD from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success Rate of experimental group</measure>
    <time_frame>Immediately after the procedure</time_frame>
    <description>Defined as the proportion of the number of ablation procedures in which the catheter would be successfully placed on the treatment site and the catheter would be successfully withdrawn after the completion of the treatment procedure in all the ablation procedures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Serious) Adverse Event Rate related to device or procedure</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Defined as the total number of events per total number of treatment years.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with TLD and standard of care (per GOLD guideline).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients will undergo sham TLD procedure and be treated with standard of care (per GOLD guideline).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TLD</intervention_name>
    <description>Patients allocated to experimental group will receive TLD therapy during which radiofrequency energy will be delivered to vagus nerve surrounding airway under bronchoscopy.</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham TLD procedure</intervention_name>
    <description>Patients allocated to control group will receive sham TLD procedure during which catheter will be placed in all treatment locations with no radiofrequency energy delivered.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Patients will also receive standard of care that meet the recommendations of GOLD guideline.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants aged ≥40 and ≤ 75 years;&#xD;
&#xD;
          2. Diagnosis of COPD with post-bronchodilator PFT parameters FEV1/FVC&lt;70% and 20% ≤ FEV1&#xD;
             ≤ 60% of predicted; if FEV1&lt;30%pred, PaCO2≤50mmHg;&#xD;
&#xD;
          3. CAT ≥ 10 or mMRC ≥2;&#xD;
&#xD;
          4. Non-smoking for a minimum of 2 months prior to consent and agrees to not smoke for the&#xD;
             duration of the clinical investigation;&#xD;
&#xD;
          5. Recent participation in a formal pulmonary rehabilitation program should have occurred&#xD;
             ≥3 months prior to consent; if participants are currently enrolled in a maintenance&#xD;
             program, they should agree to continue their current program through their 12-month&#xD;
             follow-up visit;&#xD;
&#xD;
          6. Documented history of taking standard medication (consistent with GOLD&#xD;
             guideline&lt;2022&gt;) for ≥12 months at the time of consent;&#xD;
&#xD;
          7. Received an influenza vaccine within the 12 months prior to consent or agrees to&#xD;
             obtain an influenza vaccine during the clinical investigation, and agrees to annual&#xD;
             influenza vaccines for the duration of the clinical investigation;&#xD;
&#xD;
          8. Resting SpO2 ≥ 89% at the time of screening;&#xD;
&#xD;
          9. Willing, able, and agrees to complete all protocol required baseline and follow-up&#xD;
             testing assessments including finishing the Patient Diary;&#xD;
&#xD;
         10. Able to understand the purpose of the clinical investigation, agree to participate in&#xD;
             the trial and able to complete the informed consent signature.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. BMI &lt; 18 or &gt; 35;&#xD;
&#xD;
          2. Asthma as defined by the GINA guideline (2022);&#xD;
&#xD;
          3. Patient has been previously diagnosed with a non-COPD active lung disease (e.g.,&#xD;
             active tuberculosis);&#xD;
&#xD;
          4. Patient has a medical history of pneumothorax;&#xD;
&#xD;
          5. Known contraindication or allergy to medications required for bronchoscopy or general&#xD;
             anesthesia that cannot be medically controlled;&#xD;
&#xD;
          6. Recent respiratory infections or COPD exacerbation in preceding 4 weeks;&#xD;
&#xD;
          7. Malignancy treated with radiation or chemotherapy within 2 years of consent;&#xD;
&#xD;
          8. Daily use of &gt; 10 mg of prednisone or its equivalent at the time of consent;&#xD;
&#xD;
          9. Recent (within 3 months of consent) opioid use;&#xD;
&#xD;
         10. Known gastrointestinal motility disorder or previous abdominal surgical procedure on&#xD;
             stomach, esophagus, or pancreas&#xD;
&#xD;
         11. Has an implantable electronic device;&#xD;
&#xD;
         12. Previous or planned pulmonary or thoracic surgery (including but not limited to:&#xD;
             pneumonectomy, lung transplantation, pulmonary medical device intervention &lt; e.g.&#xD;
             pulmonary valve implantation, bronchial thermal ablation (BT), etc. &gt;) during this&#xD;
             trial;&#xD;
&#xD;
         13. Myocardial infarction within last 6 months, EKG with evidence of life-threatening&#xD;
             arrhythmias or acute ischemia, pre-existing documented evidence of a LVEF &lt; 45%, stage&#xD;
             C or D (ACC/AHA) or Class III or IV (NYHA) congestive heart failure, or any other&#xD;
             cardiac findings that make the participant an unacceptable candidate for a&#xD;
             bronchoscopic procedure utilizing general anesthesia;&#xD;
&#xD;
         14. High risk of pulmonary hypertension according to clinical assessment, defined as&#xD;
             pulmonary artery systolic pressure estimated by echocardiogram to be &gt; 50 mmHg;&#xD;
&#xD;
         15. Pulmonary nodule or other lesions thought to be at high risk of malignancy;&#xD;
&#xD;
         16. Clinically relevant bronchiectasis, defined as severe single lobe or multilobar&#xD;
             bronchial wall thickening associated with airway dilation on CT scan leading to cough,&#xD;
             intractable expectoration and repeated hemoptysis lasting for several days;&#xD;
&#xD;
         17. In the opinion of the Investigator, use of the TLD devices is not feasible, for&#xD;
             example, due to screening chest CT scan reveals severe emphysema or bronchi anatomy&#xD;
             cannot be fully treated with available catheter sizes: severe bullous disease (&gt; 1/3&#xD;
             hemithorax) or site discovery of a mass that requires treatment;&#xD;
&#xD;
         18. A GCSI total symptom score ≥ 18.0 prior to treatment;&#xD;
&#xD;
         19. Any disease or condition that might interfere with completion of a procedure or this&#xD;
             study (e.g., life expectancy&lt; 1 years);&#xD;
&#xD;
         20. Women of childbearing potential must have a negative pregnancy test (blood or urine)&#xD;
             pre-treatment and agree not to become pregnant for the duration of the study&#xD;
&#xD;
         21. Participated in any clinical trial and received experimental treatment within 3 months&#xD;
             before the screening visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fengming Luo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liheng Xie</last_name>
    <phone>+8613916444591</phone>
    <email>medicalaffairs@broncuschina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Fengming Luo, M.D</last_name>
      <phone>+8618980601355</phone>
      <email>luofengming@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Fengming Luo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 20, 2023</study_first_submitted>
  <study_first_submitted_qc>April 3, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>April 3, 2023</last_update_submitted>
  <last_update_submitted_qc>April 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

